{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:22:03Z","timestamp":1792725723033,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":1377,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.7861\/clinmed.2020-0054","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T09:39:41Z","timestamp":1594892381000},"page":"417-423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?"],"prefix":"10.1016","volume":"20","author":[{"given":"Angelos","family":"Kyriacou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eka","family":"Melson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punith","family":"Kempegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.7861\/clinmed.2020-0054_bib1","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.4049\/jimmunol.0900679","article-title":"Transgenic expression of single-chain anti-CTLA-4 Fv on \u03b2 cells protects nonobese diabetic mice from autoimmune diabetes","volume":"183","author":"Shieh","year":"2009","journal-title":"J Immunol"},{"key":"10.7861\/clinmed.2020-0054_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJM200002033420501","article-title":"A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies","volume":"342","author":"Imagawa","year":"2000","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2020-0054_bib3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jdi.12024","article-title":"Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012)","volume":"3","author":"Imagawa","year":"2012","journal-title":"J Diabetes Investig"},{"key":"10.7861\/clinmed.2020-0054_bib4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/jdi.12531","article-title":"Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy","volume":"7","author":"Okamoto","year":"2016","journal-title":"J Diabetes Investig"},{"key":"10.7861\/clinmed.2020-0054_bib5","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.2337\/dc15-1331","article-title":"Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes","volume":"38","author":"Gaudy","year":"2015","journal-title":"Diabetes Care"},{"key":"10.7861\/clinmed.2020-0054_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/CMR.0000000000000418","article-title":"Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma","volume":"28","author":"Takahashi","year":"2018","journal-title":"Melanoma Res"},{"key":"10.7861\/clinmed.2020-0054_bib7","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"10.7861\/clinmed.2020-0054_bib8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12185-016-2101-4","article-title":"Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma","volume":"105","author":"Munakata","year":"2017","journal-title":"Int J Hematol"},{"key":"10.7861\/clinmed.2020-0054_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00592-016-0872-y","article-title":"Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes","volume":"53","author":"Kong","year":"2016","journal-title":"Acta Diabetol"},{"key":"10.7861\/clinmed.2020-0054_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-016-0196-z","article-title":"Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy","volume":"4","author":"Lowe","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.7861\/clinmed.2020-0054_bib11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/1346-8138.13486","article-title":"Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient","volume":"44","author":"Teramoto","year":"2017","journal-title":"J Dermatol"},{"key":"10.7861\/clinmed.2020-0054_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1620\/tjem.239.155","article-title":"Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes","volume":"239","author":"Miyoshi","year":"2016","journal-title":"Tohoku J Exp Med"},{"key":"10.7861\/clinmed.2020-0054_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1620\/tjem.244.33","article-title":"Painless thyroiditis and fulminant type 1 diabetes mellitus in a patient treated with an immune checkpoint inhibitor, nivolumab","volume":"244","author":"Sakurai","year":"2018","journal-title":"Tohoku J Exp Med"},{"key":"10.7861\/clinmed.2020-0054_bib14","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2169\/internalmedicine.9518-17","article-title":"Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of anti-PD-1 antibody","volume":"57","author":"Shiba","year":"2018","journal-title":"Intern Med"},{"key":"10.7861\/clinmed.2020-0054_bib15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/CMR.0000000000000384","article-title":"Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma","volume":"27","author":"Tsiogka","year":"2017","journal-title":"Melanoma Res"},{"key":"10.7861\/clinmed.2020-0054_bib16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.endinu.2017.01.005","article-title":"Diabetes fulminante secundaria a tratamiento con pembrolizumab","volume":"64","author":"Mizab Mellah","year":"2017","journal-title":"Endocrinol Diabetes y Nutr"},{"key":"10.7861\/clinmed.2020-0054_bib17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2217\/imt-2017-0020","article-title":"A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient","volume":"9","author":"Ara\u00fajo","year":"2017","journal-title":"Immunotherapy"},{"key":"10.7861\/clinmed.2020-0054_bib18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1684\/ejd.2016.2923","article-title":"A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms","volume":"27","author":"Ishikawa","year":"2017","journal-title":"Eur J Dermatology"},{"key":"10.7861\/clinmed.2020-0054_bib19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00262-015-1689-1","article-title":"Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report","volume":"64","author":"Martin-Liberal","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.7861\/clinmed.2020-0054_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00262-016-1913-7","article-title":"A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes","volume":"66","author":"Chae","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.7861\/clinmed.2020-0054_bib21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.7861\/clinmed.2020-0054_bib22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00262-016-1835-4","article-title":"A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome","volume":"65","author":"Hansen","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.7861\/clinmed.2020-0054_bib23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000456540","article-title":"Autoimmune diabetes and thyroiditis complicating treatment with nivolumab","volume":"10","author":"Li","year":"2017","journal-title":"Case Rep Oncol"},{"key":"10.7861\/clinmed.2020-0054_bib24","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.2337\/dc15-0889","article-title":"Anti-PD-1 and Anti-PDL-1 monoclonal antibodies causing type 1 diabetes","volume":"38","author":"Mellati","year":"2015","journal-title":"Diabetes Care"},{"key":"10.7861\/clinmed.2020-0054_bib25","first-page":"18","article-title":"Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis","volume":"2018","author":"Tzoulis","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.7861\/clinmed.2020-0054_bib26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/annonc\/mdw447","article-title":"Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma","volume":"28","author":"Tel\u00f3","year":"2017","journal-title":"Ann Oncol"},{"key":"10.7861\/clinmed.2020-0054_bib27","first-page":"4","article-title":"Diabetic ketoacidosis after treatment with pembrolizumab","volume":"5","author":"Abdul Aziz","year":"2017","journal-title":"J Clin Transl Endocrinol Case Rep"},{"key":"10.7861\/clinmed.2020-0054_bib28","article-title":"A case of nivolumab-induced fulminant type 1 diabetes with steroids and glucagon-like peptide 1 administration during the early onset","volume":"6:883","author":"Fukui","year":"2016","journal-title":"J Clin Case Rep"},{"key":"10.7861\/clinmed.2020-0054_bib29","first-page":"126","article-title":"A case of nivolumab induced fulminant type 1 diabetes","volume":"56","author":"Frunza-Stefan","year":"2018","journal-title":"Endocr Abstr"},{"key":"10.7861\/clinmed.2020-0054_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40425-017-0245-2","article-title":"Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer","volume":"5","author":"Godwin","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.7861\/clinmed.2020-0054_bib31","first-page":"17","article-title":"New-onset insulin-dependent diabetes due to nivolumab","volume":"2018","author":"Zaied","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.7861\/clinmed.2020-0054_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11523-017-0480-y","article-title":"Anti-PD-L1 atezolizumab-induced autoimmune diabetes: a case report and review of the literature","volume":"12","author":"Hickmott","year":"2017","journal-title":"Target Oncol"},{"key":"10.7861\/clinmed.2020-0054_bib33","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune diabetes induced by PD-1 inhibitor\u2014retrospective analysis and pathogenesis: a case report and literature review","volume":"66","author":"Gauci","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.7861\/clinmed.2020-0054_bib34","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2340\/00015555-2504","article-title":"Acute lower limb ischaemia and diabetes in a patient treated with anti-PD1 monoclonal antibody for metastatic melanoma","volume":"97","author":"Thoreau","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.7861\/clinmed.2020-0054_bib35","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.jtho.2016.12.015","article-title":"Association of serum anti-GAD antibody and HLA haplotypes with type 1 diabetes mellitus triggered by nivolumab in patients with non-small cell lung cancer","volume":"12","author":"Usui","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.7861\/clinmed.2020-0054_bib36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/CJI.0000000000000173","article-title":"Diabetic ketoacidosis as an immune-related adverse event from pembrolizumab in non\u2013small cell lung cancer","volume":"40","author":"Leonardi","year":"2017","journal-title":"J Immunother"},{"key":"10.7861\/clinmed.2020-0054_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.7861\/clinmed.2020-0054_bib38","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1159\/000480634","article-title":"Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the literature, and optimal management","volume":"10","author":"Kapke","year":"2017","journal-title":"Case Rep Oncol"},{"key":"10.7861\/clinmed.2020-0054_bib39","doi-asserted-by":"crossref","first-page":"066","DOI":"10.23937\/2378-3419\/3\/4\/1066","article-title":"Rapid development of type 1 diabetes mellitus after initiation of anti-PD-1 therapy","volume":"3","author":"Shah","year":"2016","journal-title":"Int J Cancer Clin Res"},{"key":"10.7861\/clinmed.2020-0054_bib40","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.4158\/EP161410.CR","article-title":"Development of type 1 diabetes after cancer immunotherapy","volume":"3","author":"Hao","year":"2017","journal-title":"AACE Clin Case Reports"},{"key":"10.7861\/clinmed.2020-0054_bib41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diabet.2016.05.007","article-title":"Autoimmune diabetes superimposed on type 2 diabetes in a patient initiated on immunotherapy for lung cancer","volume":"43","author":"Alhusseini","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.7861\/clinmed.2020-0054_bib42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.14310\/horm.2002.1656","article-title":"A case of multiple immune toxicities from ipilimumab and pembrolizumab treatment","volume":"15","author":"Asif Humayun","year":"2016","journal-title":"Hormones"},{"key":"10.7861\/clinmed.2020-0054_bib43","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor\u2013induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmed.2020-0054_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-217454","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","volume":"2016","author":"Aleksova","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.7861\/clinmed.2020-0054_bib45","first-page":"49","article-title":"Autoimmune diabetes presented with diabetic ketoacidosis induced by immunotherapy in an adult with melanoma","volume":"169","author":"Alzenaidi","year":"2017","journal-title":"J La State Med Soc"},{"key":"10.7861\/clinmed.2020-0054_bib46","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1016\/j.jtho.2017.07.021","article-title":"Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response","volume":"12","author":"Marchand","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.7861\/clinmed.2020-0054_bib47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40425-017-0303-9","article-title":"Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma","volume":"5","author":"Changizzadeh","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.7861\/clinmed.2020-0054_bib48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/TME.0000000000000173","article-title":"A case of drug-induced severe endocrinopathies what providers in the emergency department need to know","volume":"40","author":"Villarreal","year":"2018","journal-title":"Adv Emerg Nurs J"},{"key":"10.7861\/clinmed.2020-0054_bib49","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/jdi.12627","article-title":"Acute-onset type 1 diabetes mellitus caused by nivolumab in a patient with advanced pulmonary adenocarcinoma","volume":"8","author":"Kumagai","year":"2017","journal-title":"J Diabetes Investig"},{"key":"10.7861\/clinmed.2020-0054_bib50","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.clml.2017.12.008","article-title":"HIV-related refractory hodgkin lymphoma: a case report of complete response to nivolumab","volume":"18","author":"Chang","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.7861\/clinmed.2020-0054_bib51","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2217\/imt-2017-0042","article-title":"Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma","volume":"9","author":"Smith-Cohn","year":"2017","journal-title":"Immunotherapy"},{"key":"10.7861\/clinmed.2020-0054_bib52","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/CJI.0000000000000218","article-title":"Diabetes and blood glucose disorders under Anti-PD1","volume":"41","author":"Magis","year":"2018","journal-title":"J Immunother"},{"key":"10.7861\/clinmed.2020-0054_bib53","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/jdi.12679","article-title":"Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab","volume":"9","author":"Matsumura","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.7861\/clinmed.2020-0054_bib54","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00592-018-1246-4","article-title":"Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring","volume":"56","author":"Tassone","year":"2019","journal-title":"Acta Diabetol"},{"key":"10.7861\/clinmed.2020-0054_bib55","article-title":"New onset type 1 diabetes and diabetic ketoacidosis induced by nivolumab therapy","volume":"21","author":"Stevens","year":"2017","journal-title":"Proc UCLA Healthc"},{"key":"10.7861\/clinmed.2020-0054_bib56","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00592-018-1234-8","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol"},{"key":"10.7861\/clinmed.2020-0054_bib57","doi-asserted-by":"crossref","first-page":"638","DOI":"10.2337\/dc17-2243","article-title":"Anti\u2013programmed death 1 (PD-1) antibodies and the pancreas: a diabetic storm ahead","volume":"41","author":"Marchand","year":"2018","journal-title":"Diabetes Care"},{"key":"10.7861\/clinmed.2020-0054_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-220999","article-title":"New onset diabetes after nivolumab treatment","volume":"2018","author":"Capitao","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.7861\/clinmed.2020-0054_bib59","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2020-0054_bib60","doi-asserted-by":"crossref","DOI":"10.1177\/2042018819896182","article-title":"Immunotherapy-induced endocrinopathies: assessment, management and monitoring","volume":"10","author":"Nogueira","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.7861\/clinmed.2020-0054_bib61","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.7861\/clinmed.2020-0054_bib62","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"10.7861\/clinmed.2020-0054_bib63","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.7861\/clinmed.2020-0054_bib64","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.26.8.2345","article-title":"Fulminant type 1 diabetes: A nationwide survey in Japan","volume":"26","author":"Imagawa","year":"2003","journal-title":"Diabetes Care"},{"key":"10.7861\/clinmed.2020-0054_bib65","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/PL00022647","article-title":"No evidence of rapid onset (Japanese) type I diabetes in Caucasian patients","volume":"43","author":"Pozzilli","year":"2000","journal-title":"Diabetologia"},{"key":"10.7861\/clinmed.2020-0054_bib66","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet Med"},{"key":"10.7861\/clinmed.2020-0054_bib67","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1002\/ijc.31012","article-title":"The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety","volume":"141","author":"Wu","year":"2017","journal-title":"Int J Cancer"},{"key":"10.7861\/clinmed.2020-0054_bib68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.7861\/clinmed.2020-0054_bib69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.33590\/emj\/10310168","article-title":"Partial Clinical Remission of type 1 diabetes mellitus in children: clinical applications and challenges with its definitions","volume":"4","author":"Nwosu","year":"2019","journal-title":"Eur Med J Diabetes"},{"key":"10.7861\/clinmed.2020-0054_bib70","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.7861\/clinmed.2020-0054_bib71","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/jdi.12662","article-title":"Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in \u2018anti-programmed cell death protein 1 antibody-induced\u2019 fulminant type 1 diabetes","volume":"9","author":"Sakai","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.7861\/clinmed.2020-0054_bib72","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1111\/j.1572-0241.2000.03188.x","article-title":"Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA","volume":"95","author":"Nair","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.7861\/clinmed.2020-0054_bib73","doi-asserted-by":"crossref","first-page":"djw260","DOI":"10.1093\/jnci\/djw260","article-title":"Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab","volume":"109","author":"Friedman","year":"2017","journal-title":"J Natl Cancer Inst"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824035279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824035279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmed.2020-0054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:39:50Z","timestamp":1761460790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824035279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1470211824035279"],"URL":"https:\/\/doi.org\/10.7861\/clinmed.2020-0054","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmed.2020-0054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2020. All rights reserved.","name":"copyright","label":"Copyright"}]}}